Given its role in tumor biology, USP22 is being explored as a potential therapeutic target, aiming to develop novel inhibitors that could enhance the effectiveness of existing treatments and improve outcomes for NSCLC patients [38]. The gene discussed is USP22; the disease is non-small cell lung carcinoma.